Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2006-06-27
2006-06-27
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S001110, C424S001650, C424S001490, C424S001690
Reexamination Certificate
active
07067111
ABSTRACT:
The invention provides, in a general sense, a new labeling strategy employing99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
REFERENCES:
patent: 4279992 (1981-07-01), Boguslaski et al.
patent: 4418068 (1983-11-01), Jones
patent: 4507466 (1985-03-01), Tomalia et al.
patent: 4558120 (1985-12-01), Tomalia et al.
patent: 4568737 (1986-02-01), Tomalia et al.
patent: 4587329 (1986-05-01), Tomalia et al.
patent: 4631337 (1986-12-01), Tomalia et al.
patent: 4694064 (1987-09-01), Tomalia et al.
patent: 4713975 (1987-12-01), Tomalia et al.
patent: 4732863 (1988-03-01), Tomasi et al.
patent: 4737550 (1988-04-01), Tomalia
patent: 4789542 (1988-12-01), Goodman et al.
patent: 4824659 (1989-04-01), Hawthorne
patent: 4857599 (1989-08-01), Tomalia et al.
patent: 4871779 (1989-10-01), Killat et al.
patent: 4988496 (1991-01-01), Srinivasan et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5164294 (1992-11-01), Skold et al.
patent: 5268163 (1993-12-01), Verbruggen
patent: 5279811 (1994-01-01), Bergstein et al.
patent: 5356793 (1994-10-01), Koezuka et al.
patent: 5412072 (1995-05-01), Sakurai et al.
patent: 5416016 (1995-05-01), Low et al.
patent: 5517993 (1996-05-01), Unger et al.
patent: 5534241 (1996-07-01), Torchilin et al.
patent: 5605671 (1997-02-01), Lyle et al.
patent: 5635382 (1997-06-01), Low et al.
patent: 5635603 (1997-06-01), Hansen et al.
patent: 5643883 (1997-07-01), Marchase et al.
patent: 5670132 (1997-09-01), Griffiths et al.
patent: 5688487 (1997-11-01), Linder et al.
patent: 5688488 (1997-11-01), Low et al.
patent: 5730968 (1998-03-01), Butterfield et al.
patent: 5820847 (1998-10-01), Low et al.
patent: 5830431 (1998-11-01), Srinivasan et al.
patent: 5834266 (1998-11-01), Crabtree et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5891468 (1999-04-01), Martin et al.
patent: 5908777 (1999-06-01), Lee et al.
patent: 5951964 (1999-09-01), Dean et al.
patent: 5955053 (1999-09-01), Marzilli et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 5986074 (1999-11-01), Marzilli et al.
patent: 6033884 (2000-03-01), Woo et al.
patent: 6054436 (2000-04-01), Crabtree et al.
patent: 6071533 (2000-06-01), Papahadjopoulos et al.
patent: 6083741 (2000-07-01), Hart et al.
patent: 6113946 (2000-09-01), Szoka, Jr. et al.
patent: 6197278 (2001-03-01), Blankenberg et al.
patent: 6251866 (2001-06-01), Prakash et al.
patent: 6262107 (2001-07-01), Li et al.
patent: 2001/0034363 (2001-10-01), Li et al.
patent: 2001/0041189 (2001-11-01), Xu
patent: WO 91/16076 (1991-10-01), None
patent: WO 95/28966 (1995-11-01), None
patent: WO 97/33552 (1997-09-01), None
patent: WO 98/08859 (1998-03-01), None
patent: WO 99/39748 (1999-08-01), None
patent: WO 99/49901 (1999-10-01), None
patent: WO 99/61512 (1999-12-01), None
patent: WO 00/53233 (2000-09-01), None
patent: WO 00/61788 (2000-10-01), None
patent: WO 01/80906 (2001-11-01), None
patent: WO 01/91807 (2001-12-01), None
Ilgan et al, Cancer Biother. Radiopharm. (1998), 13(6), 427-435.
Mangera et al, J. Labelled Compd. Radiopharm. (1999), 42(7), 683-699.
Yang et al, Pharmaceutical Research (1999), 16(5), 743-750.
Abrams et al., “Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats,”J. Nucl. Med.,31:2022-2028, 1990.
Bakker et al., “Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals,”J. Nucl. Med.,31:1501-1509, 1990.
Blakenberg et al., “Imaging of apoptosis (programmed cell death) with99mTc annexin V.,”J. Nucl. Med.,40:184-191, 1999.
Blondeau et al., “Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid,”Can J. Chem,45:49-52, 1967.
Davison et al., “A new class of oxotechnetium(5+) chelate complexes containing a TcON2S2Core,”Inorg Chem,20:1629-1632, 1981.
Goldsmith et al., “Somatostatin receptor imaging in lymphoma,”Sem Nucl Med,25:262-271, 1995.
Goldsmith, “Receptor imaging: Competitive or complementary to antibody imaging,”Sem Nucl Med.,27:85-93, 1997.
Hadley et al, “Magnetic resonance imaging in acute head injury,”Clin. Rad.,39:131-139, 1988.
Jamar et al., “Clearance of the new tubular agent Tc-99mL,L-ethylenedicysteine: Estimation by a simplified method,”J Nucl Med,34:129P, 1993.
Jamar et al., “Clinical evaluation of Tc-99mL,L-ethylenedicysteine, a new renal tracer, in transplanted patients,”J Nucl Med, 34:129P, 1993a.
Kabasakal. “Technetium-99m ethylene dicysteine: a new renal tubular function agent,”Eur. J Nucl. Med.27:351-357, 2000.
Koh et al., “Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole,”Int J Radiat Oncol Biol Phys, 22:199-212, 1992.
Leamon and Low, “Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis,”Proc Natl Acad Sci, 88:5572-5576, 1991.
Weir et al, “Prognostic value of single-photon emission tomography in acute ischaemic strike,”Eur. Journ. Nuc. Med.,24:21-26, 1989.
Skrzypczak-Sankun et al., “Structure of the hirugen and hirulog 1 complexes of α-thrombin,”J. Mol. Biol.,221:1379-1393, 1991.
Martin et al., “Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium,”J Nucl Med,30:194-201, 1989.
Mathias et al., “Indium-111-DTPA-folate as a radiopharmaceutical for targeting tumor-associated folate binding protein,”J Nucl Med, (Supplement) 38:133P, 1997.
Mathias et al., “Synthesis of Tc-99m-DTPA-folate and preliminary evaluation as a folate-receptor-targeted radiopharmaceutical,”J Nucl Med,(Supplement); 38:87P, 1997.
Mathias et al., “Tumor-selective radiopharmaceudcal targeting via receptor- mediated endocytosis of Gallium- 67- deferoxamine- folate,”J Nucl Med,37:1003-1008, 1996.
Knight et al., “Radiolabeling of fibrinogen using the lodogen technique,”Throm. Res. Cen. Dept. Biochem.,pp. 593-596, 1982.
Rasey et al., “Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia,”Int. J. Radiat Oncol. Biol Phys, 17:985-991, 1989.
Rasey et al., “Characterization of the binding of labeled fluoromisonidazole in cells in vitro,”Radiat Res,122:301-308, 1990.
Knight et al, “Thrombus imaging with technetium—99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets,”J. Nucl. Med.,35:282-288, 1991.
Seabold et al., “Comparison of99mTc-Methoxyisobutyl Isonitrile and201T1 Scintigraphy for Detection of Residual Thyroid Cancer After131I Ablative Therapy,”J. Nucl. Med.,40(9):1434-1440, 1999.
Walsh et al., “Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infaction,”J. Nucl. Med.,30:1798-1808, 1989.
Kinji et al., “Imaging of bone infection with labelled white blood cells: role of contemporaneous bone marrow imaging,”Dept. Dia. Rad.,pp. 148-151, 1990.
Surma et al., “Usefulness of Tc-99m-N,N′-ethylene-1-dicysteine complex for dynamic kidney investigations,”Nucl Med Comm, 15:628-635, 1994.
Tubis et al., “The preparation of99mtechnetium-labelled cystine, methionine and synthetic polypetide and their distribution in mice,”Int;. Journ. Appl. Rad. Isotop., 19:835-840, 1968.
Valk et al., “Hypoxia in human gliomas: Demonstration by PET with [18F]fluoromisonid
Kim E. Edmund
Liu Chun W.
Yang David J.
Yu Dong-Fang
Board of Regents University of Texas System
Fullbright & Jaworski L.L.P.
Jones Dameron L.
LandOfFree
Ethylenedicysteine (EC)-drug conjugates, compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ethylenedicysteine (EC)-drug conjugates, compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ethylenedicysteine (EC)-drug conjugates, compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3658977